Old drug, new hope? ivermectin shows promise for PKDL in small study
NCT ID NCT07286604
First seen Dec 26, 2025 · Last updated May 12, 2026 · Updated 23 times
Summary
This early study tested the safety and effectiveness of the drug ivermectin for treating post-kala-azar dermal leishmaniasis (PKDL), a skin condition that can develop after recovery from visceral leishmaniasis. Ten otherwise healthy adults with PKDL took ivermectin pills for five days each month for three months. The study found no severe side effects and all participants had negative skin tests for the parasite after treatment, suggesting ivermectin may be a safe and convenient option for PKDL.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-KALA-AZAR DERMAL LEISHMANIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)
Dhaka, 1212, Bangladesh
Conditions
Explore the condition pages connected to this study.